Rocket Pharmaceuticals, Inc. (RCKT) 10-Year Financial Performance & Capital Metrics

RCKT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.Show more

Revenue $0
EBITDA -$264M -4.5%
Net Income -$259M -5.4%
EPS (Diluted) -2.73 +6.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.14% -8.3%
ROIC -52.08% -11.5%
Debt/Equity 0.06 +8.3%
Interest Coverage -144.86 -4.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 12.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM18.18%

ROCE

10Y Avg-37.81%

5Y Avg-42.48%

3Y Avg-50.07%

Latest-54.38%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	169K	204K	330K	426K	1.15M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-169K	-204K	-330K	-426K	-1.15M	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.76%	-0.21%	-0.62%	-0.29%	-1.69%	1%	-	-	-
Operating Expenses+	20.4M	41.88M	26.74M	70.97M	75.9M	134.86M	167.25M	224.34M	259.66M	273.2M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.84M	9.89M	12.54M	17.89M	17.53M	27.92M	41.77M	58.77M	73.32M	101.96M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	12.55M	31.98M	14.19M	53.27M	58.62M	106.38M	125.48M	165.57M	186.34M	171.24M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-186K	-250K	0	0	0	0	0
Operating Income+	-20.4M	-41.88M	-26.74M	-71.16M	-76.15M	-136M	-167.25M	-224.34M	-259.66M	-273.2M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.65%	-1.05%	0.36%	-1.66%	-0.07%	-0.79%	-0.23%	-0.34%	-0.16%	-0.05%
EBITDA+	-20.35M	-41.71M	-26.53M	-70.83M	-75.72M	-134.86M	-161.88M	-218.08M	-252.56M	-263.83M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.64%	-1.05%	0.36%	-1.67%	-0.07%	-0.78%	-0.2%	-0.35%	-0.16%	-0.04%
D&A (Non-Cash Add-back)	45K	169K	204K	330K	426K	1.15M	5.37M	6.27M	7.1M	9.38M
EBIT	-66.75M	-41.44M	-20.21M	-68.67M	-71.56M	-132.73M	-163.18M	-219.95M	-243.72M	-256.86M
Net Interest Income+	-1.14M	-975K	-2.76M	-3.55M	-1.37M	-5.4M	-2.82M	1.98M	14.06M	16.34M
Interest Income	89K	443K	819K	1.69M	3.41M	2.15M	3.07M	3.89M	15.94M	18.22M
Interest Expense	1.23M	1.42M	3.58M	5.24M	4.78M	7.55M	5.89M	1.91M	1.88M	1.89M
Other Income/Expense	-47.59M	-975K	-2.76M	-3.36M	-1.12M	-3.7M	-1.82M	2.48M	14.06M	14.46M
Pretax Income+	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-139.7M	-169.07M	-221.86M	-245.59M	-258.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	6.97M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.08%	1.05%	1%	1%	1%	1%
Net Income+	-67.98M	-42.85M	-29.5M	-74.52M	-83.23M	-146.67M	-169.07M	-221.86M	-245.59M	-258.75M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-6.13%	0.37%	0.31%	-1.53%	-0.12%	-0.76%	-0.15%	-0.31%	-0.11%	-0.05%
Net Income (Continuing)	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-146.67M	-169.07M	-221.86M	-245.59M	-258.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14.85	-6.41	-4.36	-1.89	-1.70	-2.52	-2.68	-3.26	-2.92	-2.73
EPS Growth %	-2.28%	0.57%	0.32%	0.57%	0.1%	-0.48%	-0.06%	-0.22%	0.1%	0.07%
EPS (Basic)	-10.29	-6.41	-4.36	-1.89	-1.70	-2.52	-2.68	-3.26	-2.92	-2.73
Diluted Shares Outstanding	6.61M	6.68M	6.77M	39.38M	49.01M	55.38M	63.24M	68.15M	84.01M	94.81M
Basic Shares Outstanding	6.61M	6.68M	6.77M	39.38M	49.01M	55.38M	63.24M	68.15M	84.01M	94.81M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	112.37M	128.35M	101.05M	209.09M	307.75M	487.35M	392.06M	364.06M	378.22M	378.18M
Cash & Short-Term Investments	111.28M	126.47M	100.01M	205.73M	304.12M	482.72M	388.74M	356.39M	373.18M	372.34M
Cash Only	80.04M	29.8M	78.72M	111.36M	185.38M	297.1M	232.69M	140.52M	55.9M	163.63M
Short-Term Investments	31.24M	96.67M	21.29M	94.38M	118.73M	185.62M	156.05M	215.88M	317.27M	208.7M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	3.36M	0	0	0	7.67M	5.05M	5.85M
Total Non-Current Assets+	955K	1.3M	731K	42.23M	64.37M	103.48M	104.96M	187.75M	188.12M	149.52M
Property, Plant & Equipment	812K	1.13M	563K	2.03M	31.35M	70.64M	72.35M	77.64M	87.59M	83.32M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	30.82M	30.82M	30.82M	30.82M	39.15M	39.15M	39.15M
Intangible Assets	0	0	0	0	226K	0	0	25.72M	25.15M	25.15M
Long-Term Investments	0	0	207K	7.4M	1.52M	0	0	43.28M	34.32M	0
Other Non-Current Assets	143K	168K	-39K	1.44M	1.98M	3.59M	1.8M	1.95M	1.91M	1.89M
Total Assets+	113.32M	129.65M	101.78M	251.31M	372.12M	590.82M	497.02M	551.81M	566.34M	527.7M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	19.53%	0.14%	-0.21%	1.47%	0.48%	0.59%	-0.16%	0.11%	0.03%	-0.07%
Total Current Liabilities+	4.14M	7.21M	4.07M	15.37M	18.31M	32.62M	22.17M	39.17M	48.51M	40.68M
Accounts Payable	1.63M	1.59M	451K	0	0	0	0	0	0	0
Days Payables Outstanding	13.25K	3.44K	806.94	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	957K	4.88M	0	0	0	0
Deferred Revenue (Current)	450K	478K	506K	534K	562K	590K	0	0	0	0
Other Current Liabilities	549K	2.97M	557K	12.93M	12.68M	2M	4.53M	10.01M	9.93M	11.94M
Current Ratio	27.13x	17.80x	24.83x	13.60x	16.81x	14.94x	17.69x	9.29x	7.80x	9.30x
Quick Ratio	27.13x	17.80x	24.83x	13.60x	16.81x	14.94x	17.69x	9.29x	7.80x	9.30x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	367K	49.27M	49.94M	41.9M	46.52M	54.69M	20.13M	22.95M	25.26M	23.78M
Long-Term Debt	0	48.96M	49.54M	41.45M	45.05M	35.07M	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.44M	19.49M	20.05M	20.36M	22.33M	22.64M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	367K	307K	403K	457K	23K	136K	80K	2.6M	2.94M	1.14M
Total Liabilities	4.51M	56.48M	54.01M	57.28M	64.82M	87.31M	42.3M	62.12M	73.77M	64.47M
Total Debt+	0	48.96M	49.54M	41.45M	47.45M	61.7M	22.6M	22.87M	25.04M	25.5M
Net Debt	-80.04M	19.16M	-29.18M	-69.91M	-137.93M	-235.4M	-210.09M	-117.65M	-30.86M	-138.14M
Debt / Equity	-	0.67x	1.04x	0.21x	0.15x	0.12x	0.05x	0.05x	0.05x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.58x	-29.53x	-7.47x	-13.58x	-15.92x	-18.02x	-28.40x	-117.52x	-138.48x	-144.86x
Total Equity+	108.81M	73.17M	47.76M	194.04M	307.3M	503.52M	454.72M	489.69M	492.57M	463.23M
Equity Growth %	3.11%	-0.33%	-0.35%	3.06%	0.58%	0.64%	-0.1%	0.08%	0.01%	-0.06%
Book Value per Share	16.47	10.95	7.06	4.93	6.27	9.09	7.19	7.19	5.86	4.89
Total Shareholders' Equity	108.81M	73.17M	47.76M	194.04M	307.3M	503.52M	454.72M	489.69M	492.57M	463.23M
Common Stock	264K	270K	68K	452K	548K	610K	645K	791K	903K	1.06M
Retained Earnings	-196.02M	-238.88M	-268.37M	-105.87M	-183.14M	-322.84M	-491.91M	-713.77M	-959.37M	-1.22B
Treasury Stock	0	0	263.94M	-668K	-53K	0	0	-47K	0	0
Accumulated OCI	-11K	-54K	-16K	-127K	20K	-42K	-161K	-357K	319K	66K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.42M	-37.27M	-26.11M	-53.79M	-64.66M	-74.64M	-121.16M	-178.14M	-194.92M	-209.72M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.79%	-1.14%	0.3%	-1.06%	-0.2%	-0.15%	-0.62%	-0.47%	-0.09%	-0.08%
Net Income	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-139.7M	-169.07M	-221.86M	-245.59M	-258.75M
Depreciation & Amortization	45K	169K	200K	330K	426K	1.15M	5.37M	6.27M	7.1M	9.38M
Stock-Based Compensation	2.38M	2.91M	4.04M	13.6M	13.37M	18.57M	29.24M	31.01M	39.41M	43.92M
Deferred Taxes	46.36M	225K	654K	-484K	-1.07M	999K	3.15M	0	0	0
Other Non-Cash Items	1.11M	162K	522K	2.9M	3.6M	29.32M	13.53M	370K	-9.28M	-6.19M
Working Capital Changes	669K	2.12M	-2.03M	4.38M	-3.73M	15.03M	-3.39M	6.08M	13.46M	1.92M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	487K	-41K	-1.14M	5.89M	-2.72M	11.02M	-4.83M	9.67M	0	0
Cash from Investing+	-31.68M	-66.06M	75.02M	-5.27M	-39.01M	-96.59M	18.85M	-69.33M	-98.07M	131.71M
Capital Expenditures	-412K	-487K	-70K	-1.45M	-23.27M	-29.06M	-7.71M	-8.62M	-16.47M	-5.86M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-356K	-15.74K	-8.45M	-95K	0	0	0
Cash from Financing+	125.52M	16	25.41K	153.5M	177.79M	282.99M	37.68M	155.29M	208.4M	185.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	106K	346K	19K	148K	-313K	-3.85M	-201K	-172K	-132K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.83M	-37.75M	-26.18M	-55.24M	-87.93M	-103.7M	-128.88M	-186.76M	-211.39M	-215.59M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.83%	-1.12%	0.31%	-1.11%	-0.59%	-0.18%	-0.24%	-0.45%	-0.13%	-0.02%
FCF per Share	-2.70	-5.65	-3.87	-1.40	-1.79	-1.87	-2.04	-2.74	-2.52	-2.27
FCF Conversion (FCF/Net Income)	0.26x	0.87x	0.89x	0.72x	0.78x	0.51x	0.72x	0.80x	0.79x	0.81x
Interest Paid	0	0	0	4.49M	2.99M	0	0	0	0	0
Taxes Paid	0	0	0	2K	26K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-237.48%	-47.1%	-48.78%	-61.64%	-33.2%	-36.18%	-35.29%	-46.98%	-50.01%	-54.14%
Return on Invested Capital (ROIC)	-	-51.87%	-36.16%	-74.79%	-38.92%	-46.63%	-48.93%	-54.57%	-46.72%	-52.08%
Debt / Equity	-	0.67x	1.04x	0.21x	0.15x	0.12x	0.05x	0.05x	0.05x	0.06x
Interest Coverage	-16.58x	-29.53x	-7.47x	-13.58x	-15.92x	-18.02x	-28.40x	-117.52x	-138.48x	-144.86x
FCF Conversion	0.26x	0.87x	0.89x	0.72x	0.78x	0.51x	0.72x	0.80x	0.79x	0.81x

Frequently Asked Questions

Growth & Financials

Rocket Pharmaceuticals, Inc. (RCKT) grew revenue by 0.0% over the past year. Growth has been modest.

Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $240.9M for fiscal year 2024.

Dividend & Returns

Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -54.1%. Negative ROE indicates the company is unprofitable.

Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $202.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Rocket Pharmaceuticals, Inc. (RCKT) 10-Year Financial Performance & Capital Metrics

RCKT • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$264M -4.5%
Net Income -$259M -5.4%
EPS (Diluted) -2.73 +6.5%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -54.14% -8.3%
ROIC -52.08% -11.5%
Debt/Equity 0.06 +8.3%
Interest Coverage -144.86 -4.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 12.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM6.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM18.18%

ROCE

10Y Avg-37.81%

5Y Avg-42.48%

3Y Avg-50.07%

Latest-54.38%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	169K	204K	330K	426K	1.15M	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-169K	-204K	-330K	-426K	-1.15M	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.76%	-0.21%	-0.62%	-0.29%	-1.69%	1%	-	-	-
Operating Expenses+	20.4M	41.88M	26.74M	70.97M	75.9M	134.86M	167.25M	224.34M	259.66M	273.2M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.84M	9.89M	12.54M	17.89M	17.53M	27.92M	41.77M	58.77M	73.32M	101.96M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	12.55M	31.98M	14.19M	53.27M	58.62M	106.38M	125.48M	165.57M	186.34M	171.24M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	-186K	-250K	0	0	0	0	0
Operating Income+	-20.4M	-41.88M	-26.74M	-71.16M	-76.15M	-136M	-167.25M	-224.34M	-259.66M	-273.2M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-1.65%	-1.05%	0.36%	-1.66%	-0.07%	-0.79%	-0.23%	-0.34%	-0.16%	-0.05%
EBITDA+	-20.35M	-41.71M	-26.53M	-70.83M	-75.72M	-134.86M	-161.88M	-218.08M	-252.56M	-263.83M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-1.64%	-1.05%	0.36%	-1.67%	-0.07%	-0.78%	-0.2%	-0.35%	-0.16%	-0.04%
D&A (Non-Cash Add-back)	45K	169K	204K	330K	426K	1.15M	5.37M	6.27M	7.1M	9.38M
EBIT	-66.75M	-41.44M	-20.21M	-68.67M	-71.56M	-132.73M	-163.18M	-219.95M	-243.72M	-256.86M
Net Interest Income+	-1.14M	-975K	-2.76M	-3.55M	-1.37M	-5.4M	-2.82M	1.98M	14.06M	16.34M
Interest Income	89K	443K	819K	1.69M	3.41M	2.15M	3.07M	3.89M	15.94M	18.22M
Interest Expense	1.23M	1.42M	3.58M	5.24M	4.78M	7.55M	5.89M	1.91M	1.88M	1.89M
Other Income/Expense	-47.59M	-975K	-2.76M	-3.36M	-1.12M	-3.7M	-1.82M	2.48M	14.06M	14.46M
Pretax Income+	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-139.7M	-169.07M	-221.86M	-245.59M	-258.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	6.97M	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.08%	1.05%	1%	1%	1%	1%
Net Income+	-67.98M	-42.85M	-29.5M	-74.52M	-83.23M	-146.67M	-169.07M	-221.86M	-245.59M	-258.75M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-6.13%	0.37%	0.31%	-1.53%	-0.12%	-0.76%	-0.15%	-0.31%	-0.11%	-0.05%
Net Income (Continuing)	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-146.67M	-169.07M	-221.86M	-245.59M	-258.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-14.85	-6.41	-4.36	-1.89	-1.70	-2.52	-2.68	-3.26	-2.92	-2.73
EPS Growth %	-2.28%	0.57%	0.32%	0.57%	0.1%	-0.48%	-0.06%	-0.22%	0.1%	0.07%
EPS (Basic)	-10.29	-6.41	-4.36	-1.89	-1.70	-2.52	-2.68	-3.26	-2.92	-2.73
Diluted Shares Outstanding	6.61M	6.68M	6.77M	39.38M	49.01M	55.38M	63.24M	68.15M	84.01M	94.81M
Basic Shares Outstanding	6.61M	6.68M	6.77M	39.38M	49.01M	55.38M	63.24M	68.15M	84.01M	94.81M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	112.37M	128.35M	101.05M	209.09M	307.75M	487.35M	392.06M	364.06M	378.22M	378.18M
Cash & Short-Term Investments	111.28M	126.47M	100.01M	205.73M	304.12M	482.72M	388.74M	356.39M	373.18M	372.34M
Cash Only	80.04M	29.8M	78.72M	111.36M	185.38M	297.1M	232.69M	140.52M	55.9M	163.63M
Short-Term Investments	31.24M	96.67M	21.29M	94.38M	118.73M	185.62M	156.05M	215.88M	317.27M	208.7M
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	3.36M	0	0	0	7.67M	5.05M	5.85M
Total Non-Current Assets+	955K	1.3M	731K	42.23M	64.37M	103.48M	104.96M	187.75M	188.12M	149.52M
Property, Plant & Equipment	812K	1.13M	563K	2.03M	31.35M	70.64M	72.35M	77.64M	87.59M	83.32M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	30.82M	30.82M	30.82M	30.82M	39.15M	39.15M	39.15M
Intangible Assets	0	0	0	0	226K	0	0	25.72M	25.15M	25.15M
Long-Term Investments	0	0	207K	7.4M	1.52M	0	0	43.28M	34.32M	0
Other Non-Current Assets	143K	168K	-39K	1.44M	1.98M	3.59M	1.8M	1.95M	1.91M	1.89M
Total Assets+	113.32M	129.65M	101.78M	251.31M	372.12M	590.82M	497.02M	551.81M	566.34M	527.7M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	19.53%	0.14%	-0.21%	1.47%	0.48%	0.59%	-0.16%	0.11%	0.03%	-0.07%
Total Current Liabilities+	4.14M	7.21M	4.07M	15.37M	18.31M	32.62M	22.17M	39.17M	48.51M	40.68M
Accounts Payable	1.63M	1.59M	451K	0	0	0	0	0	0	0
Days Payables Outstanding	13.25K	3.44K	806.94	-	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	957K	4.88M	0	0	0	0
Deferred Revenue (Current)	450K	478K	506K	534K	562K	590K	0	0	0	0
Other Current Liabilities	549K	2.97M	557K	12.93M	12.68M	2M	4.53M	10.01M	9.93M	11.94M
Current Ratio	27.13x	17.80x	24.83x	13.60x	16.81x	14.94x	17.69x	9.29x	7.80x	9.30x
Quick Ratio	27.13x	17.80x	24.83x	13.60x	16.81x	14.94x	17.69x	9.29x	7.80x	9.30x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	367K	49.27M	49.94M	41.9M	46.52M	54.69M	20.13M	22.95M	25.26M	23.78M
Long-Term Debt	0	48.96M	49.54M	41.45M	45.05M	35.07M	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.44M	19.49M	20.05M	20.36M	22.33M	22.64M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	367K	307K	403K	457K	23K	136K	80K	2.6M	2.94M	1.14M
Total Liabilities	4.51M	56.48M	54.01M	57.28M	64.82M	87.31M	42.3M	62.12M	73.77M	64.47M
Total Debt+	0	48.96M	49.54M	41.45M	47.45M	61.7M	22.6M	22.87M	25.04M	25.5M
Net Debt	-80.04M	19.16M	-29.18M	-69.91M	-137.93M	-235.4M	-210.09M	-117.65M	-30.86M	-138.14M
Debt / Equity	-	0.67x	1.04x	0.21x	0.15x	0.12x	0.05x	0.05x	0.05x	0.06x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-16.58x	-29.53x	-7.47x	-13.58x	-15.92x	-18.02x	-28.40x	-117.52x	-138.48x	-144.86x
Total Equity+	108.81M	73.17M	47.76M	194.04M	307.3M	503.52M	454.72M	489.69M	492.57M	463.23M
Equity Growth %	3.11%	-0.33%	-0.35%	3.06%	0.58%	0.64%	-0.1%	0.08%	0.01%	-0.06%
Book Value per Share	16.47	10.95	7.06	4.93	6.27	9.09	7.19	7.19	5.86	4.89
Total Shareholders' Equity	108.81M	73.17M	47.76M	194.04M	307.3M	503.52M	454.72M	489.69M	492.57M	463.23M
Common Stock	264K	270K	68K	452K	548K	610K	645K	791K	903K	1.06M
Retained Earnings	-196.02M	-238.88M	-268.37M	-105.87M	-183.14M	-322.84M	-491.91M	-713.77M	-959.37M	-1.22B
Treasury Stock	0	0	263.94M	-668K	-53K	0	0	-47K	0	0
Accumulated OCI	-11K	-54K	-16K	-127K	20K	-42K	-161K	-357K	319K	66K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.42M	-37.27M	-26.11M	-53.79M	-64.66M	-74.64M	-121.16M	-178.14M	-194.92M	-209.72M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-0.79%	-1.14%	0.3%	-1.06%	-0.2%	-0.15%	-0.62%	-0.47%	-0.09%	-0.08%
Net Income	-67.98M	-42.85M	-29.5M	-74.52M	-77.27M	-139.7M	-169.07M	-221.86M	-245.59M	-258.75M
Depreciation & Amortization	45K	169K	200K	330K	426K	1.15M	5.37M	6.27M	7.1M	9.38M
Stock-Based Compensation	2.38M	2.91M	4.04M	13.6M	13.37M	18.57M	29.24M	31.01M	39.41M	43.92M
Deferred Taxes	46.36M	225K	654K	-484K	-1.07M	999K	3.15M	0	0	0
Other Non-Cash Items	1.11M	162K	522K	2.9M	3.6M	29.32M	13.53M	370K	-9.28M	-6.19M
Working Capital Changes	669K	2.12M	-2.03M	4.38M	-3.73M	15.03M	-3.39M	6.08M	13.46M	1.92M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	487K	-41K	-1.14M	5.89M	-2.72M	11.02M	-4.83M	9.67M	0	0
Cash from Investing+	-31.68M	-66.06M	75.02M	-5.27M	-39.01M	-96.59M	18.85M	-69.33M	-98.07M	131.71M
Capital Expenditures	-412K	-487K	-70K	-1.45M	-23.27M	-29.06M	-7.71M	-8.62M	-16.47M	-5.86M
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	-356K	-15.74K	-8.45M	-95K	0	0	0
Cash from Financing+	125.52M	16	25.41K	153.5M	177.79M	282.99M	37.68M	155.29M	208.4M	185.74M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	106K	346K	19K	148K	-313K	-3.85M	-201K	-172K	-132K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-17.83M	-37.75M	-26.18M	-55.24M	-87.93M	-103.7M	-128.88M	-186.76M	-211.39M	-215.59M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-0.83%	-1.12%	0.31%	-1.11%	-0.59%	-0.18%	-0.24%	-0.45%	-0.13%	-0.02%
FCF per Share	-2.70	-5.65	-3.87	-1.40	-1.79	-1.87	-2.04	-2.74	-2.52	-2.27
FCF Conversion (FCF/Net Income)	0.26x	0.87x	0.89x	0.72x	0.78x	0.51x	0.72x	0.80x	0.79x	0.81x
Interest Paid	0	0	0	4.49M	2.99M	0	0	0	0	0
Taxes Paid	0	0	0	2K	26K	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-237.48%	-47.1%	-48.78%	-61.64%	-33.2%	-36.18%	-35.29%	-46.98%	-50.01%	-54.14%
Return on Invested Capital (ROIC)	-	-51.87%	-36.16%	-74.79%	-38.92%	-46.63%	-48.93%	-54.57%	-46.72%	-52.08%
Debt / Equity	-	0.67x	1.04x	0.21x	0.15x	0.12x	0.05x	0.05x	0.05x	0.06x
Interest Coverage	-16.58x	-29.53x	-7.47x	-13.58x	-15.92x	-18.02x	-28.40x	-117.52x	-138.48x	-144.86x
FCF Conversion	0.26x	0.87x	0.89x	0.72x	0.78x	0.51x	0.72x	0.80x	0.79x	0.81x

Frequently Asked Questions

Growth & Financials

Rocket Pharmaceuticals, Inc. (RCKT) grew revenue by 0.0% over the past year. Growth has been modest.

Rocket Pharmaceuticals, Inc. (RCKT) reported a net loss of $240.9M for fiscal year 2024.

Dividend & Returns

Rocket Pharmaceuticals, Inc. (RCKT) has a return on equity (ROE) of -54.1%. Negative ROE indicates the company is unprofitable.

Rocket Pharmaceuticals, Inc. (RCKT) had negative free cash flow of $202.8M in fiscal year 2024, likely due to heavy capital investments.